Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Update

$Sagimet Biosciences(SGMT.US)$ Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
SAN MATEO, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ("Sagimet") (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the commencement of an underwritten public offering of 9,000,000 shares of its Series A common stock. All of the shares in the proposed offering are to be sold by Sagimet. In addition, Sagimet expects to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of its Series A common stock in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
10
Translate
Report
6553 Views
Comment
Sign in to post a comment
2505Followers
28Following
33KVisitors
Follow